dc.creator | Mauri D., Tzachanis D., Valachis A., Kamposioras K., Tolia M., Dambrosio M., Zarkavelis G., Gkoura S., Gazouli I., de Lorenzo F., Apostolidis K. | en |
dc.date.accessioned | 2023-01-31T08:58:03Z | |
dc.date.available | 2023-01-31T08:58:03Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 11070625 | |
dc.identifier.uri | http://hdl.handle.net/11615/76429 | |
dc.description.abstract | To protect cancer patients from COVID-19exposure, prioritization strategies are being implemented at global level. Measures include use of tele-health services, deferring elective surgeries, delaying non life-saving therapies, interrupting maintenance and supportive care regimens and suspending screening and regular follow-up visits. Nonetheless, the risk of infection may not always outweigh oncology treatment benefit. Lives of most oncology patients depend on their ability to receive medical, surgical and radiotherapy care. Postponing screening, follow-up and radical surgeriesincreasepatients’riskofdevelopingmetastaticdisease. Aviral pandemic lasts long time andexhibits seasonal and geographical variations. Though vaccines will be available only in the 2021, a global, aggressive, all-embracing and protracted slowdown of oncologic activities will severely jeopardize patients’ outcomes. A present international oncologists’ panel, ECPC and FAVO, strongly suggest that Hospital measures in a specific geographical area/Nation should be in line with the local epidemic, and restrictions adopted should be adapted and stratified over time. © 2020 Zerbinis Publications. All rights reserved. | en |
dc.language.iso | en | en |
dc.source | Journal of B.U.ON. | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090103978&partnerID=40&md5=628efbaca8b244b56007e9aae61fc339 | |
dc.subject | cancer patient | en |
dc.subject | coronavirus disease 2019 | en |
dc.subject | human | en |
dc.subject | medical society | en |
dc.subject | Northern Hemisphere | en |
dc.subject | pandemic | en |
dc.subject | panic | en |
dc.subject | Review | en |
dc.subject | seasonal variation | en |
dc.subject | Southern Hemisphere | en |
dc.subject | clinical trial | en |
dc.subject | communicable disease control | en |
dc.subject | Coronavirus infection | en |
dc.subject | Europe | en |
dc.subject | global health | en |
dc.subject | mortality | en |
dc.subject | multicenter study | en |
dc.subject | neoplasm | en |
dc.subject | oncology | en |
dc.subject | organization and management | en |
dc.subject | pandemic | en |
dc.subject | practice guideline | en |
dc.subject | risk assessment | en |
dc.subject | survival analysis | en |
dc.subject | telemedicine | en |
dc.subject | virus pneumonia | en |
dc.subject | Communicable Disease Control | en |
dc.subject | Coronavirus Infections | en |
dc.subject | Europe | en |
dc.subject | Global Health | en |
dc.subject | Humans | en |
dc.subject | Medical Oncology | en |
dc.subject | Neoplasms | en |
dc.subject | Pandemics | en |
dc.subject | Pneumonia, Viral | en |
dc.subject | Practice Guidelines as Topic | en |
dc.subject | Risk Assessment | en |
dc.subject | Survival Analysis | en |
dc.subject | Telemedicine | en |
dc.subject | Zerbinis Publications | en |
dc.title | Behind the numbers and the panic of a viral pandemic: Fixed restrictive oncology guidance may jeopardize patients’ survival | en |
dc.type | other | en |